Triantennary GalNAc-1

Triantennary GalNAc-1 is a triantennary N-acetylgalactosamine (GalNAc) that can be conjugated to the 3' end of the sense strand of siRNA. GalNAc promotes targeted delivery of siRNA to liver cells both in vitro and in vivo[1].

CC(N[C@H]([C@H]([C@H]([C@H](O1)CO)O)O)[C@@H]1OCCCCC(NCCCNC(CCOCC(COCCC(NCCCNC(CCCCO[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)NC(C)=O)=O)=O)(NC(CCCCCCCCCCC(N3[C@@H](C[C@H](C3)O)COP(O)(O)=O)=O)=O)COCCC(NCCCNC(CCCCO[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)NC(C)=O)=O)=O)=O)=O)=O

[1]Nair JK, Willoughby JL, Chan A, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136(49):16958-16961. |[2]Nair JK, Attarwala H, Sehgal A, et al. Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates. Nucleic Acids Res. 2017;45(19):10969-10977.